Broadwood Partners Reports Ownership Change in Insight Molecular Diagnostics
Ticker: IMDX · Form: 4 · Filed: Apr 20, 2026 · CIK: 0001642380
Sentiment: neutral
Topics: insider-filing, ownership-change
TL;DR
Broadwood Partners adjusted their stake in Insight Molecular Diagnostics on 4/16.
AI Summary
On April 16, 2026, Broadwood Partners, L.P. reported a change in beneficial ownership of securities for Insight Molecular Diagnostics Inc. The filing details transactions related to their holdings, with Broadwood Capital Inc. and Neal C. Bradsher also listed as reporting entities. The filing was accepted by the SEC on April 20, 2026.
Why It Matters
This filing indicates shifts in significant ownership stakes, which can signal changes in investor sentiment or strategy regarding Insight Molecular Diagnostics Inc.
Risk Assessment
Risk Level: medium — Form 4 filings can indicate insider trading or significant shifts in institutional ownership, which may impact stock price.
Key Players & Entities
- Broadwood Partners, L.P. (company) — Reporting entity for changes in beneficial ownership
- Insight Molecular Diagnostics Inc. (company) — Issuer of the securities
- Broadwood Capital Inc. (company) — Related reporting entity
- Neal C. Bradsher (person) — Related reporting entity
- 2026-04-16 (date) — Period of report for ownership change
- 2026-04-20 (date) — Filing acceptance date
FAQ
What specific transactions were reported by Broadwood Partners, L.P. on April 16, 2026?
The filing indicates a change in beneficial ownership, but the specific transaction details (e.g., buy/sell, number of shares, price) are not provided in this summary document.
Who are the other entities involved in this filing?
Broadwood Capital Inc. and Neal C. Bradsher are also listed as reporting entities in this Form 4 filing.
What is the CIK number for Insight Molecular Diagnostics Inc.?
The CIK number for Insight Molecular Diagnostics Inc. is 0001642380.
When was this Form 4 filing accepted by the SEC?
This Form 4 filing was accepted by the SEC on April 20, 2026.
What is the primary business of Insight Molecular Diagnostics Inc.?
Insight Molecular Diagnostics Inc. is involved in 'In Vitro & In Vivo Diagnostic Substances'.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 20, 2026 by Neal C. Bradsher regarding Insight Molecular Diagnostics Inc. (IMDX). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.